Skip to content

Explore the effect of ivarabradine in patients with acute myocardial infarction complicated with left heart pump failure under PICCO monitoring

Explore the effect of ivarabradine in patients with acute myocardial infarction complicated with left heart pump failure under PICCO monitoring

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900028134
Enrollment
Unknown
Registered
2019-12-13
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ST segment elevation myocardial infarction

Interventions

Sponsors

First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. the first onset of acute myocardial infarction; 2. the blood flow at culprit coronary artery after PCI meets TIMI 3; 3. sinus rhythm and > 100 times/min; 4. systolic pressure <=110mmHg; 5. echocardiography showed left ventricular ejection fraction <=45%; 6. All patients received standard doses of dual antiplatelet therapy (aspirin + ADP receptor inhibitor) and statin.

Exclusion criteria

Exclusion criteria: 1. the blood flow at culprit coronary artery after PCI didn't reach TIMI3; 2. complicated with non-culprit lesions requiring intervention during this hospital stay; 3. sustained rapid atrial/ventricular arrhythmia; 4. sick sinus syndrome, II to III degree atrioventricular block; 5. IABP implantation; 6. moderate or severe anemia; 7. hyperthyroidism or hypothyroidism; 8. previous history of myocardial infarction; 9. complicating mechanical complications after myocardial infarction (ventricular septum perforation/papillary muscular insufficiency/cardiac rupture); 10. complicated with heart valvular disease or other diagnosed heart disease; 11. hemorrhagic disease; 12. Severe liver dysfunction (Child-Pugh score >=10 points) or end stage of renal failure (Creatinine clearance <15ml/min); 13. malignant tumor; 14. poor adherence; 15. using the sedative drugs; 16. involved in other clinical study.

Design outcomes

Primary

MeasureTime frame
cardiac output;heart rate;stroke volume;mean arterial pressure;Brachial arterial blood pressure;

Secondary

MeasureTime frame
NT-proBNP;LVEF;

Countries

China

Contacts

Public ContactXiaojuan Fan

First Affiliated Hospital of Xi'an Jiaotong University

colors727@163.com+86 18829029900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026